Trent Woodruff

Dr Woodruff is a Professor of Pharmacology who leads a research team aiming to find new therapeutic treatments for neurodegenerative disorders. Current therapies for these diseases are vastly inadequate, and so new research is needed to identify novel targets to slow or halt their progression. Prof Woodruff's specific research revolves around the innate immune system in the brain, and the role of neuroinflammation in propagating disease. A key focus of his current work is testing new drugs developed at the University of Queensland in models of motor neuron disease (amyotrophic lateral sclerosis), Huntington's disease, and Parkinson's disease, as well as maintaining an active interest in acute inflammatory disorders including sepsis and ischemia-reperfusion injuries. Using a series of potent and orally active complement C5a and NLRP3 inflammasome inhibitors developed at UQ, Prof Woodruff's team has demonstrated the therapeutic potential of targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of these neurodegenerative diseases. His team has recently shown that in addition to their roles in neurodegeneration, innate immune factors also play essential roles in stem and neuronal cell development during embryogenesis, revealing the widespread physiological and pathological roles of this evolutionarily ancient immune system. Neurodegenerative disease, Parkinson's disease, Motor neuron disease, Immunology, Neurosciences, Pharmacology and pharmaceutical sciences

[2025] Ischaemic endothelial necroptosis induces haemolysis and COVID-19 angiopathy. Nature, 643 (8070), 182-191. doi: 10.1038/s41586-025-09076-x [2025] Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis. British Journal of Pharmacology, 182 (16), 3852-3869. doi: 10.1111/bph.70056 [2025] A New Era for Complement Therapeutics. Journal of Allergy and Clinical Immunology, 156 (2), 1-3. doi: 10.1016/j.jaci.2025.04.006 [2025] Peripheral and central elevation of IL-8 in patients with Huntington's disease. Molecular Immunology, 179, 84-93. doi: 10.1016/j.molimm.2025.02.003 [2024] Inhibiting Eph/ephrin signaling reduces vascular leak and endothelial cell dysfunction in mice with sepsis. Science Translational Medicine, 16 (744) eadg5